Situación actual de las vacunas atenuadas intranasales frente al virus respiratorio sincitial en la población infantil

Abstract

The respiratory syncytial virus (RSV) is the cause of acute respiratory pathologies (bronchiolitis and pneumonia), which occur preferably in the pediatric population in an epidemic manner. The only way to prevent these infections is through prior vaccination of children older than 6 months. Of the different existing vaccines, attenuated vaccines, defined as those that contain an altered or modified virus to minimize its pathogenic capacity while maintaining its immunological response capacity, seem to represent an important advance. In recent years, two vaccine candidates based on the M2-2 gene deletion have been evaluated, those designated MEDI/ΔM2 and LID/ΔM2-2/1030s. In the study carried out in 21 seronegative children (6-24 months), they received an intranasal dose (10⁵ PFU) of the new vaccine compared to a placebo group. Eighty-five percent of those vaccinated developed a neutralizing antibody titer  4 times greater than the previous one. The combination of the Δ1313 deletion with the NS2 deletion was shown to be better for the development of an attenuated RSV recombinant vaccine candidate (ΔNS2/Δ1313), with good protective results. A new vaccine candidate designated RSV/6120/ΔNS2/1030s was developed that is identical to the previous virus RSV/ΔNS2/Δ1313/I1314L but with additional mutations. Finally, a RSV with a single replicative cycle has been developed by eliminating the gene encoding the matrix (M) protein (RSV-M-null). Most of these vaccines are still in phase 2/3 and very good results are expected.